BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)
- GenFleet to design and execute randomized Phase 2b triple combination trial of Motixafortide in first-line metastatic PDAC patients in China - - BioLineRx to retain global rights to Motixafortide... | June 28, 2022